Evidence map›Paper›PMID 30327565›Full record

ArticleBritish journal of cancer2018

CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer.

Akira Ooki, Christopher J VandenBussche, Max Kates, Noah M Hahn, Andres Matoso, David J McConkey, Trinity J Bivalacqua, Mohammad Obaidul Hoque

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 46 citations in OpenAlex.

  1. Article
  2. Integrin α6 Targeted Tumor Theranostics.Phenomics (Cham, Switzerland) · 2025
    Review
  3. CD24 as a Novel Radiopharmaceutical Target for Hepatocellular Carcinoma.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
    Article
  4. Review
  5. Article
  6. ECT2NPJ precision oncology · 2025
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Dielectric properties of urine in relation to bladder cancer.Physical and engineering sciences in medicine · 2024
    Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Akira OokiDepartment of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA.
Christopher J VandenBusscheDepartment of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21231-2410, USA.
Max KatesDepartment of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Noah M HahnDepartment of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Andres MatosoDepartment of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21231-2410, USA.
David J McConkeyDepartment of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Trinity J BivalacquaDepartment of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.
Mohammad Obaidul HoqueDepartment of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD, 21231, USA. mhoque1@jhmi.edu.
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

Treatment of HIV- and HIV+ Patients with HPV16+ CIN2/3 Using pNGLV4a-hCRTE6E7L2 DNA vaccine administered intramuscularly via electroporationP50CA098252 · NCI · JOHNS HOPKINS UNIVERSITY · PI TZYY-CHOOU WU · 2003 to 2026
$53.5M
NCI NIH HHS P50 CA098252
6 · The paper itself

Abstract

backgroundCD24 is a cornerstone of tumour progression in urothelial carcinoma of the bladder (UCB). However, its contribution to cancer stem cell (CSC)-like traits and the clinical utility of CD24 as a urinary biomarker for cancer detection have not been determined.

methodsThe functional relevance of CD24 was evaluated using in vitro and in vivo approaches. The clinical utility of CSC-related molecules was assessed in urine samples by quantitative RT-PCR.

resultsThe knockdown of CD24 attenuated cancer stemness properties. The high-CD24-expressing cells, isolated from patient-derived UCB xenograft tumours, exhibited their enhanced stemness properties. CD24 was overexpressed not only in primary tumours but also in urine from UCB subjects. By assessment of 15 candidate CSC-related molecules in urine samples of a training cohort, a panel of three molecules (CD24, CD49f, and NANOG) was selected. The combination of these three molecules yielded a sensitivity and specificity of 81.7% and 74.3%, respectively, in an independent cohort. A combined set of 84 cases and 207 controls provided a sensitivity and specificity of 82% and 76%, respectively.

conclusionCD24 has a crucial role in maintaining the urothelial cancer stem-like traits and a panel of CSC-related molecules has potential as a urinary biomarker for non-invasive UCB detection.

Indexed as

AdultAgedAged, 80 and overAnimalsBiomarkers, TumorCD24 AntigenFemaleHumansIntegrin alpha6MaleMiceMice, Inbred NODMice, KnockoutMice, SCIDMiddle AgedNanog Homeobox ProteinBiomarkers, TumorCD24 AntigenCD24 protein, humanIntegrin alpha6Nanog Homeobox ProteinNANOG protein, humanRNA, Small Interfering

Identifiers

PMID30327565
PMCPMC6203855
OpenAlexW2897922562

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.